|
rs1860661
|
|
|
0.810 |
GeneticVariation |
BEFREE |
We identify a novel variant at 19p13.3 associated with HL (rs1860661; odds ratio (OR)=0.81, 95% confidence interval (95% CI) = 0.76-0.86, P(combined) = 3.5 × 10(-10)), located in intron 2 of TCF3 (also known as E2A), a regulator of B- and T-cell lineage commitment known to be involved in HL pathogenesis.
|
24920014 |
2014 |
|
rs20541
|
|
|
0.810 |
GeneticVariation |
BEFREE |
We searched for an association between the interleukin 4 receptor gene (IL4R) rs1805015 and interleukin 13 gene (IL13) rs20541 polymorphisms and the development of antibodies to hepatitis B surface antigen (anti-HBs) in the case of hepatitis B virus (HBV) vaccination or infection in hemodialysis (HD) patients.
|
23462527 |
2013 |
|
rs649775
|
|
|
0.710 |
GeneticVariation |
BEFREE |
We identify 5 new HL risk loci at 6p21.31 (rs649775; <i>P</i> = 2.11 × 10<sup>-10</sup>), 6q23.3 (rs1002658; <i>P</i> = 2.97 × 10<sup>-8</sup>), 11q23.1 (rs7111520; <i>P</i> = 1.44 × 10<sup>-11</sup>), 16p11.2 (rs6565176; <i>P</i> = 4.00 × 10<sup>-8</sup>), and 20q13.12 (rs2425752; <i>P</i> = 2.01 × 10<sup>-8</sup>).
|
30194254 |
2018 |
|
rs3212227
|
|
|
0.030 |
GeneticVariation |
BEFREE |
3' untranslated region A>C (rs3212227) polymorphism of Interleukin 12B gene as a potential risk factor for Hodgkin's lymphoma in Brazilian children and adolescents.
|
31277552 |
2019 |
|
rs568408
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Polymorphisms of IFNL3 rs8099917 and IL12A rs568408 contribute to survival of HD patients, but not as independent factors.
|
28525983 |
2017 |
|
rs3212227
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The IL-12A rs568408 and IL-12B rs3212227 polymorphisms were analyzed in relation to anti-HBs development in 602 HD patients with negative antibodies to HBV core antigen (anti-HBc) who were hepatitis B vaccinated (group I) as well as in 237 anti-HBc positive HD patients who were infected with HBV in the past (group II).
|
24158609 |
2013 |
|
rs568408
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The IL-12A rs568408 and IL-12B rs3212227 polymorphisms were analyzed in relation to anti-HBs development in 602 HD patients with negative antibodies to HBV core antigen (anti-HBc) who were hepatitis B vaccinated (group I) as well as in 237 anti-HBc positive HD patients who were infected with HBV in the past (group II).
|
24158609 |
2013 |
|
rs3212227
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In the logistic regression analysis, the higher frequency of rs360719 CC individually (2.9% in 207 patients without anti-HBs development vs 8.0% in 311 patients with anti-HBs development, p = 0.009) and of rs360719 CC combined with rs568408 GG (p = 0.048), rs568408 GA (p = 0.035), rs568408 GG/AA (p = 0.034) or rs3212227 AA (p = 0.046) was associated with an increased chance for the development of anti-HBs in HD patients.
|
22863216 |
2012 |
|
rs568408
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In the logistic regression analysis, the higher frequency of rs360719 CC individually (2.9% in 207 patients without anti-HBs development vs 8.0% in 311 patients with anti-HBs development, p = 0.009) and of rs360719 CC combined with rs568408 GG (p = 0.048), rs568408 GA (p = 0.035), rs568408 GG/AA (p = 0.034) or rs3212227 AA (p = 0.046) was associated with an increased chance for the development of anti-HBs in HD patients.
|
22863216 |
2012 |
|
rs12917
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Recently, we detected the single nucleotide polymorphism (SNP) rs12917 (C/T) in the MGMT sequence adjacent to the active site in Hodgkin lymphoma (HL) cell line KM-H2.
|
30945122 |
2019 |
|
rs1801725
|
|
|
0.020 |
GeneticVariation |
BEFREE |
CASR polymorphisms (rs7652589, rs1801725) are associated with dyslipidemia in HD patients.
|
31775661 |
2019 |
|
rs7652589
|
|
|
0.020 |
GeneticVariation |
BEFREE |
CASR polymorphisms (rs7652589, rs1801725) are associated with dyslipidemia in HD patients.
|
31775661 |
2019 |
|
rs1800795
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Subgroup analysis indicated that rs1800795 was significantly associated with increased risk of cervical cancer, colorectal cancer, breast cancer, prostate cancer, lung cancer, glioma, non-Hodgkin's lymphoma and Hodgkin's lymphoma but not gastric cancer and multiple myeloma.
|
29552316 |
2018 |
|
rs1801725
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Homozygosity of the rs1801725 variant allele contributes to infection-related mortality in HD patients.
|
29763933 |
2018 |
|
rs8099917
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The IFNL4 rs8099917 T allele and anti-HBs development in response to HBV vaccine are associated with better survival in hemodialysis (HD) patients.
|
30259815 |
2018 |
|
rs12917
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Results indicated the presence of all the rs2308321 (I143 V), rs2308327 (K178R) and rs12917 (L84F) MGMT-variants, which were previously associated with temozolomide myelotoxicity. rs12917 (L84F) variant was reported as associating with lesser risk of gallbladder tumours, yet with higher risk of non-Hodgkin lymphomas related with exposure to chlorinated solvents or hair dyes.
|
28436299 |
2017 |
|
rs8099917
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Polymorphisms of IFNL3 rs8099917 and IL12A rs568408 contribute to survival of HD patients, but not as independent factors.
|
28525983 |
2017 |
|
rs7652589
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We aimed to determine the associations of rs7652589 with nephrolithiasis-related ESRD, Ca, P, ALP, PTH, response to treatment with cinacalcet, prevalence of coronary artery disease, and all-cause/cardiovascular mortality in HD patients (n = 1162).
|
27739473 |
2016 |
|
rs1800795
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The IL-6 promoter rs1800795 and rs1800797 were not associated with overall susceptibility to non-Hodgkin's lymphomas.
|
24059848 |
2013 |
|
rs1042522
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This meta-analysis indicates that the p53 Arg72Pro polymorphism may contribute to susceptibility to non-Hodgkin lymphomas.
|
23029260 |
2012 |
|
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This meta-analysis indicates that the p53 Arg72Pro polymorphism may contribute to susceptibility to non-Hodgkin lymphomas.
|
23029260 |
2012 |
|
rs1695
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The GSTP1 rs1695 A-allele reduced the risk for HL (GG vs. AG, OR 0.64 [0.42-0.99], p = 0.04; GG vs. AG/AA combined genotypes, OR 0.70 [0.47-1.04], p = 0.07), and the GSTT1 deleted genotype increased the risk for HL (OR 3.17 [1.97-5.09], p < 0.001) regardless of age.
|
22475179 |
2012 |
|
rs878854066
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This meta-analysis indicates that the p53 Arg72Pro polymorphism may contribute to susceptibility to non-Hodgkin lymphomas.
|
23029260 |
2012 |
|
rs1042522
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We found no association of R72P with the risk of NHL and HL development [OR(ArgPro/ProPro)=0.9 (95% CI 0.7-1.2) and 1.2 (95% CI 0.9-1.5), respectively] or with survival.
|
21546086 |
2011 |
|
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We found no association of R72P with the risk of NHL and HL development [OR(ArgPro/ProPro)=0.9 (95% CI 0.7-1.2) and 1.2 (95% CI 0.9-1.5), respectively] or with survival.
|
21546086 |
2011 |